Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
YOKNEAM, Israel, March 24, 2017 -- Lumenis Ltd., the world’s largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced today their support of the fourth annual Worldwide Endometriosis March (EndoMarch), an international event bringing together women and supporters to raise awareness of endometriosis. This year’s EndoMarch will be celebrated on Saturday, March 25, 2017, while the entire month of March is dedicated to awareness efforts and empowering women with education and knowledge.
The global EndoMarch movement began in 2014 with the purpose of uniting women from around the world in order to increase visibility of endometriosis, a disorder in which the tissue that lines a woman’s uterus, or the endometrium, disruptively grows outside of the uterus onto other organs. Endometriosis most concerning symptoms include infertility which occurs in up to half of women affected by this condition and chronic pelvic pain, as well as pain during sexual intercourse and massive bleeding which interferes with leading a normal life.
While there is no cure for endometriosis, Lumenis’ unique UltraPulse® DUO and AcuPulse™ DUO are two advanced surgical CO2 lasers, utilizing either the free-beam laser delivery or the flexible FiberLase™ fiber, designed to operate precisely around valuable and delicate pelvic anatomy with minimal thermal damage while keeping healthy tissue intact. Maintaining healthy tissue intact is especially important when the goal of therapy is to preserve and protect a woman’s fertility. The result of this type of delicate surgery is a precise removal of endometriosis lesions, significant improvement of disease symptoms and overall improvement in patient quality of life.
The strong collaboration between Lumenis and leading fertility and endometriosis surgeons worldwide results in advanced patient driven surgical technology that supports better patient care. Committed to continuously supporting endometriosis patients worldwide, Lumenis introduced www.gynhealth.com, an educational website for patients and their supporters. Visitors to the site can find disease information and an overview of surgical treatment options.
“Endometriosis, though treatable, is one of the most overlooked epidemics facing the world today. Since women often erroneously attribute their symptoms to other causes related to reproductive health, they may be diagnosed later and remain untreated. These diagnostic delays may result in increased severity of the condition and challenges in conception,” said Camran Nezhat, MD, FACOG, FACS, founder of the Worldwide EndoMarch. “EndoMarch calls on all women worldwide, those fighting endometriosis and supporters, to collectively raise awareness. Population and patient education are key in fighting this disease.”
The Worldwide EndoMarch will take place in many cities across the U.S., including San Francisco, New York, Washington, D.C., and spans internationally to India, Germany, Nigeria, Brazil, Australia and more. The largest chapter event will be held in San Francisco, where a group of Lumenis employees will participate and support the movement.
“Endometriosis impacts around 200 million women worldwide – that’s one in 10 women,” said Tzipi Ozer-Armon, CEO of Lumenis. “The advanced UltraPulse® DUO system demonstrates once again our commitment to developing technology that is dedicated to improving gynecological-related health conditions. EndoMarch serves as an ideal platform to educate women about endometriosis, its symptoms, risks and the treatment options available. We are pleased to be part of this annual international event and take action in driving awareness on an ongoing basis.”
To learn more about Lumenis CO2 Laser technology for the treatment of endometriosis please visit: http://www.lumenis.com/Solutions/Surgical/Procedures/Gynecology.
About Lumenis
www.lumenis.com
Lumenis is the world’s largest energy-based medical device company for surgical, aesthetic and ophthalmic applications in the area of minimally invasive clinical solutions. Regarded as a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. For more information visit: www.lumenis.com
MEDIA CONTACT Cassandra Dump, Pascale Communications [email protected] 619.971.1887
